Rezetamig - CISMeF

Preferred Label : Rezetamig;

NCIt synonyms : CD22 x CD3 Bispecific Antibody JNJ-75348780; Anti-CD22/CD3 Bispecific Antibody JNJ-75348780;

NCIt definition : A human bispecific antibody, with potential antineoplastic activity. Rezetamig contains two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the T-cell surface antigen CD3. Upon administration, rezetamig binds to both CD3 on T-cells and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B-cells. CD22 is exclusively expressed on B-cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.;

UNII : M8FA2JKW5P;

CAS number : 2795115-07-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2795115-07-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : JNJ-75348780; JNJ 75348780;

NCI Metathesaurus CUI : CL1647860;

Details

Origin ID

C178408;

UMLS CUI

C5555015;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Cell Receptor CD22 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients